TD Cowen analyst Ritu Baral raised the firm’s price target on Palvella Therapeutics (PVLA) to $133 from $97 and keeps a Buy rating on the shares. The target increase reflects the Ph2 CVM data update. Cowen increased QTORIN rapa’s PoS in CVM to 55%. Given the lack of spontaneous regression, similarities between the CVM-IGA and FDA accepted Ph3 MLM-IGA EP, they moved QTORIN rapa’s CVM launch year to 2029.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics granted FDA Fast Track Designation to QTORIN
- Palvella Therapeutics price target raised to $204 from $148 at Canaccord
- Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results
- Palvella Therapeutics price target raised to $174 from $110 at Chardan
- Palvella Therapeutics price target raised to $190 from $105 at Truist